UK Trials First Ebola Vaccine Using COVID-19 Platform
The phase 1 study will test safety and immune response in 50 healthy adults as researchers race to address a strain with no approved vaccine.
- On Monday, the University of Oxford launched the first human trial of a vaccine against Bundibugyo ebolavirus, seeking to combat the outbreak spreading in the Democratic Republic of Congo and Uganda.
- The Bundibugyo species has caused two previous outbreaks and currently spreads through Congo, where confirmed cases rose to 1,926, including 702 deaths, the country's public health institute said on Monday.
- Scientists at the Oxford Vaccine Group and Pandemic Sciences Institute developed the shot using the same viral vector platform as the AstraZeneca Covid vaccine; the Serum Institute of India stockpiled around 620,000 doses.
- The early-stage trial, known as BD-Ebov, will evaluate safety and immune response in 50 healthy adults aged 18 to 55, with The Coalition for Epidemic Preparedness Innovations investing up to $8.6 million.
- Chief investigator Dr. Katrina Pollock noted that Ebola species are "sisters rather than twins," requiring distinct vaccines; researchers plan further clinical studies in Uganda with year-long volunteer monitoring.
61 Articles
61 Articles
The World Health Organization (WHO) has announced that the first clinical study to assess the effectiveness of an antiviral drug in patients exposed to the deadly strain of the Ebola virus affecting the Democratic Republic of Congo has begun, reports AFP and Agerpres.
57 Days After Ebola Declaration, a Medical Milestone
Just 57 days after an Ebola emergency was declared, the UK has cleared the first human trial of a new vaccine targeting the strain behind the current outbreak in the Democratic Republic of Congo. The University of Oxford shot its candidate to the front of the pack—four vaccines are...
The World Health Organization announced on Tuesday the launch of the first clinical trial to evaluate the effectiveness of an experimental drug against a deadly strain of the Ebola virus. Developed by Gilead Sciences, the antiviral obeldesivir will be tested on nearly 1,000 asymptomatic patients exposed to Bundibugyo, the variant spreading in the Democratic Republic of Congo.
Just 57 Days After Ebola Emergency? Oxford Scientists Fast-Track New Vaccine as Deadly Outbreak Continues to Grow
Oxford scientists are preparing human trials of a new Ebola vaccine just 57 days after the WHO declared the DRC outbreak a global health emergency. The experimental vaccine targets the deadly Bundibugyo strain as the outbreak continues to grow.
Coverage Details
Bias Distribution
- 44% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
